Magnesium

Magnesium

SCHEMBL29514747

Clc1cccnc1-n1nc(Br)cc1Br.[Mg]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 3/20 0.38
CYP17A1 P05093 1/20 0.34
CYP1A2 P05177 1/20 0.34
TRPV1 Q8NER1 3/20 0.33
HSD11B1 P28845 2/20 0.33
OPRL1 P41146 3/20 0.32
KCNH2 Q12809 3/20 0.32
TRPA1 O75762 1/20 0.32
BACE1 P56817 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30658613 0.98 DHODH (0.39) DHODHCYP17A1CYP1A2TRPV1HSD11B1
SCHEMBL3254036 0.98 DHODH (0.39) DHODHCYP17A1CYP1A2TRPV1HSD11B1
SCHEMBL23249649 0.97 DHODH (0.38) DHODHCYP17A1CYP1A2TRPV1HSD11B1
SCHEMBL29101597 0.83 DHODH (0.40) DHODHCYP17A1CYP1A2TRPV1HSD11B1
SCHEMBL28411296 0.83 DHODH (0.38) DHODHCYP17A1CYP1A2TRPV1HSD11B1
SCHEMBL29101572 0.83 DHODH (0.38) DHODHCYP17A1CYP1A2TRPV1HSD11B1
SCHEMBL29437213 0.83 DHODH (0.42) DHODHCYP17A1CYP1A2TRPV1HSD11B1
SCHEMBL12528202 0.83 DHODH (0.42) DHODHCYP17A1CYP1A2TRPV1HSD11B1
SCHEMBL22315221 0.80 DHODH (0.37) DHODHCYP17A1CYP1A2TRPV1OPRL1
SCHEMBL3418088 0.79 DHODH (0.38) DHODHCYP17A1CYP1A2TRPV1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219455-B1 METHODS FOR THE PREPARATION OF A HALOGENATED PYRAZOLE FMC CORP (US) 2024-12-11 EP disclosed
US-20240300901-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC IP TECHNOLOGY GMBH (CH) 2024-09-12 US disclosed
EP-4043451-B1 METHODS FOR THE PREPARATION OF AN INTERMEDIATE IN THE SYNTHESIS OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC CORP (US) 2024-02-28 EP disclosed
EP-4284793-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC Corporation (US) 2023-12-06 EP disclosed
EP-4253380-A2 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC Corporation (US) 2023-10-04 EP disclosed
EP-4219455-A1 METHODS FOR THE PREPARATION OF A HALOGENATED PYRAZOLE FMC Corporation (US) 2023-08-02 EP disclosed
EP-3976591-B1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC CORP (US) 2023-04-19 EP disclosed
EP-3976589-B1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC CORP (US) 2023-04-12 EP disclosed
US-20220396560-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC IP TECHNOLOGY GMBH (CH) 2022-12-15 US disclosed
US-20220259178-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC IP TECHNOLOGY GMBH (CH) 2022-08-18 US disclosed
WO-2022164871-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC CORPORATION (US) 2022-08-04 WO disclosed
EP-3976589-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC CORPORATION (US) 2022-04-06 EP disclosed
EP-3976591-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID FMC Corporation (US) 2022-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300901-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID TUBA3C, KYAT3, AADAC DHODH 410/4885CYP17A1 1696/4885CYP1A2 48/4885
US-20220259178-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID KYAT3, PDXK, CBR3 DHODH 257/4885CYP17A1 1403/4885CYP1A2 15/4885
US-20220396560-A1 METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID KYAT3, PDXK, CBR3 DHODH 257/4885CYP17A1 1403/4885CYP1A2 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.